Literature DB >> 19531637

Treatment of spontaneously hypertensive rats with rosiglitazone ameliorates cardiovascular pathophysiology via antioxidant mechanisms in the vasculature.

Maria A Potenza1, Sara Gagliardi, Leonarda De Benedictis, Addolorata Zigrino, Edy Tiravanti, Giuseppe Colantuono, Antonio Federici, Loredana Lorusso, Vincenzo Benagiano, Michael J Quon, Monica Montagnani.   

Abstract

Oxidative stress contributes to cardiovascular complications of diabetes, in part, by reducing the bioavailability of nitric oxide (NO). We investigated the mechanisms whereby the insulin sensitizer rosiglitazone may ameliorate oxidative stress in the vasculature of spontaneously hypertensive rats (SHR). Nine-week-old SHR were treated by gavage for 7 wk with rosiglitazone (5 mg x kg(-1) x day(-1)) or vehicle control. Treatment of SHR with rosiglitazone lowered systolic blood pressure, reduced fasting plasma insulin and asymmetrical dimethylarginine, and increased insulin sensitivity (when compared with vehicle treatment). In vessel homogenates and serum from rosiglitazone-treated SHR, SOD activity was enhanced, while 8-iso-PGF(2alpha) (lipid peroxidation product) was reduced (when compared with samples from vehicle-treated SHR). Moreover, expression of p22phox (catalytic subunit of NADPH oxidase) as well as nitrotyrosine and superoxide content were all reduced in the aortas of rosiglitazone-treated SHR. In mesenteric vascular beds (MVB) isolated ex vivo from rosiglitazone-treated SHR, NO-dependent vasodilator actions of insulin were improved when compared with MVB from vehicle-treated SHR. Acute pretreatment of MVB from vehicle-treated SHR with apocynin (NADPH oxidase inhibitor) enhanced vasodilator actions of insulin (results comparable to those in MVB from rosiglitazone-treated SHR). In Langendorff heart preparations from rosiglitazone-treated SHR, ischemia/reperfusion injury caused infarcts 40% smaller than in hearts from vehicle-treated SHR. Acute pretreatment of hearts from vehicle-treated SHR with apocynin produced similar results. Finally, rosiglitazone treatment of endothelial cells in primary culture reduced superoxide induced by insulin-resistant conditions. We conclude that rosiglitazone therapy in SHR increases SOD activity and decreases p22phox expression in the vasculature to reduce oxidant stress leading to an improved cardiovascular phenotype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19531637      PMCID: PMC2739701          DOI: 10.1152/ajpendo.00291.2009

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  76 in total

1.  Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; Curt D Furberg
Journal:  JAMA       Date:  2007-09-12       Impact factor: 56.272

Review 2.  Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage.

Authors:  Ranganath Muniyappa; Sihoon Lee; Hui Chen; Michael J Quon
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-10-23       Impact factor: 4.310

3.  Comparison between surrogate indexes of insulin sensitivity and resistance and hyperinsulinemic euglycemic clamp estimates in mice.

Authors:  Sihoon Lee; Ranganath Muniyappa; Xu Yan; Hui Chen; Lilly Q Yue; Eun-Gyoung Hong; Jason K Kim; Michael J Quon
Journal:  Am J Physiol Endocrinol Metab       Date:  2007-11-14       Impact factor: 4.310

4.  Rosiglitazone reduces glucose-induced oxidative stress mediated by NAD(P)H oxidase via AMPK-dependent mechanism.

Authors:  Giulio Ceolotto; Alessandra Gallo; Italia Papparella; Lorenzo Franco; Ellen Murphy; Elisabetta Iori; Elisa Pagnin; Gian Paolo Fadini; Mattia Albiero; Andrea Semplicini; Angelo Avogaro
Journal:  Arterioscler Thromb Vasc Biol       Date:  2007-10-04       Impact factor: 8.311

5.  Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure.

Authors:  Taishi Nakamura; Eiichiro Yamamoto; Keiichiro Kataoka; Takuro Yamashita; Yoshiko Tokutomi; Yi-Fei Dong; Shinji Matsuba; Hisao Ogawa; Shokei Kim-Mitsuyama
Journal:  Stroke       Date:  2007-09-20       Impact factor: 7.914

Review 6.  Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials.

Authors:  Rodrigo M Lago; Premranjan P Singh; Richard W Nesto
Journal:  Lancet       Date:  2007-09-29       Impact factor: 79.321

7.  Decreasing intracellular superoxide corrects defective ischemia-induced new vessel formation in diabetic mice.

Authors:  Daniel J Ceradini; Dachun Yao; Raymon H Grogan; Matthew J Callaghan; Diane Edelstein; Michael Brownlee; Geoffrey C Gurtner
Journal:  J Biol Chem       Date:  2008-01-28       Impact factor: 5.157

Review 8.  Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning.

Authors:  Peter Ferdinandy; Rainer Schulz; Gary F Baxter
Journal:  Pharmacol Rev       Date:  2007-11-29       Impact factor: 25.468

Review 9.  Cardiovascular actions of insulin.

Authors:  Ranganath Muniyappa; Monica Montagnani; Kwang Kon Koh; Michael J Quon
Journal:  Endocr Rev       Date:  2007-05-24       Impact factor: 19.871

10.  Apocynin is not an inhibitor of vascular NADPH oxidases but an antioxidant.

Authors:  Sabine Heumüller; Sven Wind; Eduardo Barbosa-Sicard; Harald H H W Schmidt; Rudi Busse; Katrin Schröder; Ralf P Brandes
Journal:  Hypertension       Date:  2007-12-17       Impact factor: 10.190

View more
  14 in total

1.  Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline.

Authors:  Lei Yu; Xin Jin; Yang Yang; Ningren Cui; Chun Jiang
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

2.  15-Deoxy-∆12,14-PGJ 2, by activating peroxisome proliferator-activated receptor-gamma, suppresses p22phox transcription to protect brain endothelial cells against hypoxia-induced apoptosis.

Authors:  Jui-Sheng Wu; Hsin-Da Tsai; Chien-Yu Huang; Jin-Jer Chen; Teng-Nan Lin
Journal:  Mol Neurobiol       Date:  2013-12-19       Impact factor: 5.590

3.  Rosiglitazone selectively inhibits K(ATP) channels by acting on the K(IR) 6 subunit.

Authors:  Lei Yu; Xin Jin; Ningren Cui; Yang Wu; Zhenda Shi; Daling Zhu; Chun Jiang
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

4.  PPAR-γ Ameliorates Neuronal Apoptosis and Ischemic Brain Injury via Suppressing NF-κB-Driven p22phox Transcription.

Authors:  Jui-Sheng Wu; Hsin-Da Tsai; Wai-Mui Cheung; Chung Y Hsu; Teng-Nan Lin
Journal:  Mol Neurobiol       Date:  2015-06-25       Impact factor: 5.590

5.  Sesamin ameliorates arterial dysfunction in spontaneously hypertensive rats via downregulation of NADPH oxidase subunits and upregulation of eNOS expression.

Authors:  Jun-xiu Zhang; Jie-ren Yang; Guo-xiang Chen; Li-juan Tang; Wen-xing Li; Hui Yang; Xiang Kong
Journal:  Acta Pharmacol Sin       Date:  2013-04-29       Impact factor: 6.150

Review 6.  Does peroxisome proliferator-activated receptor-gamma (PPAR gamma) protect from hypertension directly through effects in the vasculature?

Authors:  Pimonrat Ketsawatsomkron; Christopher J Pelham; Séverine Groh; Henry L Keen; Frank M Faraci; Curt D Sigmund
Journal:  J Biol Chem       Date:  2010-02-03       Impact factor: 5.157

7.  Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 diabetes mellitus.

Authors:  Saher Hamed; Benjamin Brenner; Anat Aharon; Deeb Daoud; Ariel Roguin
Journal:  Cardiovasc Diabetol       Date:  2009-10-30       Impact factor: 9.951

8.  Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro.

Authors:  Elena Matsa; Paul W Burridge; Kun-Hsing Yu; John H Ahrens; Vittavat Termglinchan; Haodi Wu; Chun Liu; Praveen Shukla; Nazish Sayed; Jared M Churko; Ningyi Shao; Nicole A Woo; Alexander S Chao; Joseph D Gold; Ioannis Karakikes; Michael P Snyder; Joseph C Wu
Journal:  Cell Stem Cell       Date:  2016-08-18       Impact factor: 24.633

9.  Nutraceutical agents with anti-inflammatory properties prevent dietary saturated-fat induced disturbances in blood-brain barrier function in wild-type mice.

Authors:  Ryusuke Takechi; Menuka M Pallebage-Gamarallage; Virginie Lam; Corey Giles; John C Mamo
Journal:  J Neuroinflammation       Date:  2013-06-19       Impact factor: 8.322

10.  Intermittent losartan administration triggers cardiac post-conditioning in isolated rat hearts: role of BK2 receptors.

Authors:  Luca Sgarra; Valentina Leo; Francesco Addabbo; Dominga Iacobazzi; Maria Rosaria Carratù; Monica Montagnani; Maria Assunta Potenza
Journal:  PLoS One       Date:  2014-02-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.